Large studies on early stage HER2-positive breast cancer have shown that adding an anti-HER2 monoclonal antibody to chemotherapy reduces 10-year mortality by a third from 21.1% to 14.7% and correspondingly the recurrence rate from 31.9% to 22.9% (19), and the same research team reported later that while a long-term risk of distant recurrence remains, it is about a tenth lower in the time period after anti-HER2 therapy was introduced (20). The gene discussed is ERBB2; the disease is breast carcinoma.